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ABSTRACT

RESEARCH SETTINGS

DATA COLLECTION AND ANALYSIS

A pilot study to test the feasibility of a matched pair case-control study to explore what clinical
characteristics, treatment outcomes, and epidemiological characteristics of adult oncology
patients hospitalized with COVID-19 infection. The study was conducted at the University of
Texas MD Anderson Cancer Center using the charts of patients hospitalized from March, 2020 to
August 2020. Each patient who tested positive for COVID-19 (case) was matched for age,
gender, and cancer diagnosis with a control who tested negative for COVID-19. Total of 21 casecontrol pairs (n=42), were included in this study. Data was collected on Palantir platform using
the Core Case Record Form and Supplemental Case Record Form.

The study is conducted at the University of Texas MD Anderson Cancer Center which is a
comprehensive cancer care hospital that provides cancer care to all different types of cancers.
The study subjects are patients admitted to the hospital during the six-month period from March
1st, 2020, to August 31st, 2020. Patient charts for hospital admission prior to March 1st was not
reviewed for this study.

The Core Case Record Form and the Supplemental Case Record Form of the ISARIC-WHO
Severe Acute Respiratory Infection Clinical Characterization Tools developed by the
International Severe Acute Respiratory and Emerging Infection Consortium (ISARIC) were used
for data collection (International Severe Acute Respiratory and Emerging Infection Consortium,
2020).
All data was collected and analyzed on the Palantir platform using the coding languages R and
Python. For the numeric data, mean, standard deviation, and median were calculated.
Independent t-test and Mann Whitney test to confirm the results of numerical data and Fisher’s
exact test for categorical variables were used for assessing the statistical significance of
differences in categorical variables

The clinical characteristics associated with COVID-19 were found to be symptoms of fever,
cough, sore throat, myalgia, arthralgia, fatigue, headache, and abdominal pain (p <.001);
development of acute lung injury and use of antihyperglycemics (p <.05). The risk factors
associated with the diagnosis of COVID-19 were higher weight, increased body mass index,
obesity as defined by clinical staff, as well as Hispanic and African American ethnicities (p <.05).
There was no significant difference between the cases and controls in the length of hospital stay,
death at the time of discharge, or 30-day readmission. This study validates the feasibility of main
study and provides preliminary findings to guide future research.

BACKGROUND
Coronavirus disease 2019 (COVID-19) is novel disease known to humans for only for a period of
under one year. While COVID-19 is a pandemic that has affected over 200 countries of the
world, the knowledge base on the nature of the disease and on effective treatments of the
patients is limited and is constantly evolving as there are more and more data becomes available
from scientific studies (Coronaviridae Study Group of the International Committee on Taxonomy
of Viruses, 2020). Cancer patients are at increased risk of developing severe illness from
COVID-19, and every patient affected by this disease provides valuable information to the
understanding of the disease.
Patients with cancer are a unique population who have several risk factors for morbidity and
mortality due to their cancer diagnosis and the related treatments. Therefore, it is essential to
understand the clinical course of COVID-19 in patients with cancer. Understanding the clinical
course of these patients will provide the insight necessary for health care providers in the early
diagnosis, effective management, and prevention of complications of the patients with cancer
with COVID-19 infection. Additionally, the study results can guide clinical researchers to conduct
prospective studies in this regard.
The proposed study is important to nursing because, nurses in primary nursing roles and
advanced nursing provider roles are at the forefront of managing patients with COVID-19. In the
study setting, many advanced practice registered nurses (APRNs) in collaboration with the
physicians are directly involved in diagnosing and treating oncology patients with COVID-19. The
findings of the study would be a valuable in their understanding of the disease as well as
managing these patients effectively.

RESEARCH QUESTIONS
1.
2.
3.

What clinical characteristics of hospitalized adult oncology patients are associated with
COVID-19 diagnosis?
What treatment outcomes of hospitalized adult oncology patients are associated with
COVID-19 diagnosis?
What risk factors of hospitalized adult oncology patients are associated with COVID-19
diagnosis?

POPULATION AND SAMPLING
The current study is a pilot study conducted on 10% of the samples of the major study. 21 cases
who tested positive for COVID-19 and the 21 matched pair controls who tested negative for
COVID-19 are included in this retrospective chart review done on the Palantir platform (Palantir
Foundry, n.d.). Please refer to Figure 1 for the sample selection process for the pilot study.

Figure 1. Sample selection process for the Pilot Study

RESULTS
There was no significant difference between cases and controls in any of the matching variables
such as age, gender, cancer histology, cancer site, and cancer behavior.
The clinical characteristics associated with COVID-19 diagnosis were found to be the presenting
symptoms of fever, cough, sore throat, myalgia, arthralgia, fatigue, headache, and abdominal
pain; development of respiratory distress during the hospitalization, and the use of red blood cell
transfusions and antihyperglycemics. History of fever, cough, sore throat, myalgia, arthralgia,
fatigue or malaise, headache, abdominal pain were the most frequently reported signs and
symptoms at the time of admission; and each of these symptoms was significantly (p <.001)
associated with the diagnosis of COVID-19. Development of respiratory distress during the
hospitalization was the most frequent (57.1% in cases vs 4.8 % in controls) complication
developed by the patients who tested positive for COVID-19 and was found to be significantly (p
<.001) associated with the diagnosis of COVID-19. Use of red blood cell transfusion was lower
among the cases (9.5% in cases vs 42.9% in controls) and was found to be significantly (p <.05)
associated with the patients who tested negative for COVID-19. Please see Table 1 for the
comparison of clinical characteristics between cases and controls.
The risk factors associated with COVID-19 diagnosis were found to be body weight, BMI,
obesity, ethnicity, and chronic neurological disorder. Higher weight, increased body mass index,
as well as obesity as defined by clinical staff were significantly (p <.05) associated with the
diagnosis of COVID-19. Please see Table 2 for the comparison of risk factors between cases
and controls. While patients of Hispanic ethnicity (38.1% cases and 14.3% controls) and African
American ethnicity (28.6% cases and 14.3% controls) had higher association with COVID-19
diagnosis, patients of Asian ethnicity (0% cases and 9.5% controls) and Caucasian ethnicity
(28.6% of cases and 61.9% controls) had comparatively lower association with COVID-19
diagnosis. Please see Figure 2 for the comparison of the ethnic groups between cases and
controls.
There was no significant difference between the cases and controls in the length of hospital
stay, discharge status or destination, death during hospitalization, death within 30 days of
discharge, death within 90 days of discharge, or readmission within 30 days of discharge.
Please see Table 4 for the comparison of outcomes between cases and controls.

Figure 2. Comparison of the Ethnic Groups Between Cases and Controls

RESEARCH DESIGN
A matched pair case-control study using retrospective chart review was used to explore what
clinical characteristics, treatment outcomes, and risk factors of adult oncology patients
hospitalized with COVID-19 infection. In the ratio of 1:1, each patient who tested positive for
COVID-19 (case) was matched for age, gender, and current cancer diagnosis- in terms of cancer
histology, cancer site, and disease behavior- with a control patient who tested negative for
COVID-19. The study was conducted in collaboration with Data-Driven Determinants for COVID19 Oncology Discovery Effort (D3CODE) which is an IRB approved and activated protocol that
supports and oversees studies done on COVID-19.

CLINICAL CHARACTERISTICS OF COVID-19

RISK FACTORS OF COVID-19

Table 1. Comparison of the Clinical Characteristics of Cases and Controls

Table 2. Comparison of the Risk Factors of Cases and Controls

Comparison of the Clinical Characteristics Between Cases and Controls
Signs and symptoms at the time of
admission
History of fever
Cough
Bloody sputum/hemoptysis
Sore throat
Runny nose (Rhinorrhea)
Nasal congestion
Chest pain
Muscle aches (Myalgia)
Joint pain (Arthralgia)
Fatigue / Malaise
Shortness of Breath (Dyspnea)
Headache
Complications Developed During
Hospitalization
Bacterial pneumonia
Acute respiratory distress syndrome
Respiratory failure
Altered mental status
Endocarditis/ Myocarditis/ Pericarditis
Cardiac arrhythmia
Coagulation Disorder
Acute Renal injury
Hepatomegaly
Deep venous thrombosis
Acidosis
Treatment received any time during
hospitalization
ICU admission
Oxygen Therapy
Invasive ventilation (any)
Red blood cells
Medications administered during
hospitalization
Anticoagulants
Antihyperglycemics
Cardiovascular drugs

Cases (n=21)

Controls (n=21) P

14 (66.7%)
14 (66.7%)
2 (9.5%)
12 (57.1%)
1 (4.8%)
1 (4.8%)
2 (9.5%)
12 (57.1%)
12 (57.1%)
8 (38.1%)
14 (66.7%)
12 (57.1%)
Cases (n=21)

6 (28.6%)
0 (0%)
1 (4.8%)
0 (0%)
0 (0%)
0 (0%)
3 (14.3%)
0 (0%)
0 (0%)
1 (4.8%)
8 (38.1%)
0 (0%)
Controls (n=21)

.029
<.001
.999
<.001
.999
.999
.999
<.001
<.001
.020
.121
<.001
P

1 (4.8%)
12 (57.1%)
8 (38.1%)
1 (4.8%)
1 (4.8%)
4 (19.0%)
1 (4.8%)
2 (9.5%)
1 (4.8%)
1 (4.8%)
2 (9.5%)

1 (4.8%)
1 (4.8%)
3 (14.3%)
1 (4.8%)
0 (0%)
3 (14.3%)
3 (14.3%)
4 (19.0%)
0 (0%)
0 (0%)
2 (9.5%)

.999
<.001
.159
.999
.999
.999
.606
.663
.999
.999
.999

6 (28.6%)
19 (90.5%)
3 (14.3%)
2 (9.5%)
Cases (n=21)

4 (19.0%)
19 (90.5%)
3 (14.3%)
9 (42.9%)
Controls (n=21)

.481
.999
.999
.032
P

19 (90.5%)
20 (95.2%)
13 (61.9%)

19 (90.5%)
14 (66.7%)
11 (52.4%)

.999
.045
.756

Comparison of the Risk Factors Between Cases and Controls
Demographics
Cases (n=21)
Weight in Kg
Mean (SD)
96.7 (25.0)
Median [Min, Max]
91.0 [56.0, 155]
BMI
Mean (SD)
33.5 (7.06)
Median [Min, Max]
31.0 [24.0, 48.0]
BMI by Group
Underweight <18.5
0 (0%)
Normal weight: 18.5- <25
1 (4.8%)
Overweight: >= 25-30
7 (33.3%)
Obese: >= 30
13 (61.9%)
Ethnic group
Asian
0 (0%)
Hispanic or Latino
6 (28.6%)
Black or African American
8 (38.1%)
White or Caucasian
6 (28.6%)
Other
1 (4.8%)
Comorbidities and Risk factors
Cases (n=21)
Chronic cardiac disease (not
14 (66.7%)
hypertension)
Chronic kidney disease
5 (23.8%)
Moderate or severe liver disease
3 (14.3%)
Hemiplegia/paraplegia
2 (9.5%)
Obesity (as defined by clinical staff)
5 (23.8%)
Diabetes with complications
3 (14.3%)
Hypertension
17 (81.0%)
COPD
1 (4.8%)
Asthma
5 (23.8%)
Smoking
Current smoking
1 (4.8%)
Former smoking
7 (33.3%)
Never smoked
15 (71.4%)

Controls (n=21)

P

82.4 (18.9)
82.0 [53.0, 131]

.044

29.1 (6.64)
28.0 [18.0, 49.0]

.047

1 (4.8%)
3 (14.3%)
9 (42.9%)
8 (38.1%)

.274

2 (9.5%)
3 (14.3%)
3 (14.3%)
13 (61.9%)
0 (0%)
Controls (n=21)
18 (85.7%)

.048

7 (33.3%)
9 (42.9%)
0 (0%)
0 (0%)
4 (19.0%)
15 (71.4%)
1 (4.8%)
4 (19.0%)

.734
.085
.488
.048
.999
.719
.999
.999

1 (4.8%)
8 (38.1%)
11 (52.4%)

.999
.999
.341

P
.277

The values are reported as number and percentage. P value < .05 is considered significant.

OUTCOMES OF COVID-19
Table 3. Comparison of the Outcomes of Cases and Controls

The values are reported as number and percentage. P value < .05 is considered significant.

Comparison of the Outcomes Between Cases and Controls
Outcomes of hospitalization
Length of hospital stay
Mean (SD)
Median [Min, Max]
Alive at discharge
Home with self-care/family caregiver
Home with home health or physical
therapy
Hospice
Acute care hospital
Died at discharge
Readmission within 30 days
Death within 30 days
Death within 90 days

Cases (n=21)

Controls (n=21)

P

10.0 (9.77)
7.00 [3.00, 40.0]
20 (95.2%)
16 (76.2%)
3 (14.3%)

7.14 (6.03)
4.00 [1.00, 25.0]
19 (90.5%)
17 (81.0%)
1 (4.8%)

.254

0 (0%)
1 (4.8%)
1 (4.8%)
15 (71.4%)
2 (9.5%)
2 (9.5%)

1 (4.8%)
0 (0%)
2 (9.5%)
19 (90.5%)
4 (19.0%)
6 (28.6%)

.999
.999
.999
.238
.663
.238

.999
.999
.606

The values are reported as number and percentage. P value < .05 is considered significant.

DISCUSSION
This pilot study validates the feasibility of the study in terms of subject eligibility, matching procedure, data collection, and analysis. This study has several methodological advantages. Use of individually matched casecontrol design controls the influence of age, gender, and current cancer diagnosis. The case-control design also decreases the variance in the clinical characteristics, outcomes, and risk factors of the oncology patients
admitted with COVID-19, and thus improve statistical efficiency.
Consistent with current evidence (Lighter, et al., 2020; Hur, et al., 2020; Simonnet, et al., 2020; Kalligeros, et al., 2020; Palaiodimos, et al., 2020; Petrilli, et al., 2020; Ko, et al., 2020; Tartof, et al., 2020), this study found
that higher weight, increased body mass index, and obesity are significant risk factors associated the diagnosis of COVID-19 among hospitalized oncology population.
Unlike the existing evidence for the association of smoking (Zheng, et al., 2020; Lippi & Henry, 2020; Patanavanich & Glantz, 2020; Guo, 2020; Zhao, et al., 2020; Alqahtani, et al., 2020; Li, et al.,
2020; Farsalinos, Barbouni, Poulas, Polosa, Caponnetto, & Niaura, 2020) and type 2 diabetes mellitus (Richardson, et al., 2020; Bode, et al., 2020; Chen, et al., 2020; Fadini, Morieri, Longato, & Avogaro, 2020; Barron, et
al., 2020) with COVID-19 diagnosis and severity of illness in general population, this study did not find significant association of smoking or type 2 diabetes mellitus with the hospitalized oncology population.
The current study, finding significant association of black and Hispanic ethnicity with COVID-19 hospitalization among oncology population, is in line with existing evidence.
Similar to this pilot study, other studies (Li, et al, 2020; Menni, et al., 2020; Saeed, Sellevoll, Young, Sandbaek, Glomsaker, & Mala, 2020; Matar, et al., 2020) have also documented fever, cough, sore throat, myalgia,
arthralgia, fatigue or malaise, headache, abdominal pain, conjunctivitis, and skin rash as presenting symptoms of COVID-19 in general population. However, only limited evidence is available (Moujaess, Kourie, & Ghosn,
2020; Kuderer, et al., 2020; Zhang, et al., 2020) to characterize the clinical manifestation of COVID-19 in oncology population.
In contrast to other studies (Mehta, et al., 2020; Afshar, et al., 2020; et al., Meyerowitz-Katz & Merone, 2020; 2020; Lee, et al., 2020; Robilotti, et al., 2020; Miyashita, et al., 2020; Mehta, et al., 2020; Dai, et al., 2020;
Docherty, et al., 2020; Richardson, et al., 2020; Goyal, et al., 2020; Deng, et al., 2020; Guan, et al., 2020), this study did not find any significant differences in the discharge outcomes or 30-day mortality for the oncology
population hospitalized with COVID-19 and those who tested negative for COVID-19.
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